Pfizer UK is incredibly proud to learn the results of PatientView ‘Corporate Reputation of Pharma’ survey 2021.
For the second year in a row, Pfizer was ranked first for overall corporate reputation in the UK in 2021, according to over 100 respondent UK patient groups who have either worked directly with us or are familiar with the company.
In addition, Pfizer was ranked first out of 13 ‘big-pharma’ companies for overall corporate reputation.
The PatientView survey collected the opinions of 111 UK-based patient groups between November 2021- February 2022 on various indicators of both the pharmaceutical industry as a whole and individual companies during 2021.
"To be ranked first amongst our peers by the patient community is a great testament to Pfizer UK’s purpose. We are very proud of Pfizer’s history of putting patients at the heart of our work. We recognise the importance of harnessing the power of patient experiences and believe that only through working together can we truly understand what is needed to deliver better healthcare for people who need it. We are honoured that the patient community has recognised our commitment and look forward to continued partnering with patient organisations that share in our purpose to deliver breakthroughs that change patients’ lives”
Susan Rienow, Country President, Pfizer UK
As explained in PatientView, over the last few years where patients have struggled to access their standard healthcare practitioners due to COVID-19 restraints, patient organisations have played a major role in filling the void. As we slowly begin to return to a new normal, the life sciences industry has a responsibility to listen to the unique and changing needs of patients. We must continue to work with patient organisations on their vital work to safeguard continued access to treatment and to understand their need for holistic support ‘beyond the pill’.
At Pfizer UK, we have several key areas of interest when we consider how to partner with others to better serve patient communities. Our partnering activities encompass:
Identifying specific needs of patients and how we can better support them;
Harnessing these insights so that we can always put the patient need first; and,
Operating with a high degree of transparency so we can be confident and proud of the relationships we’ve developed.
We are pleased to see our efforts recognised but look forward to continued collaborations and improvements in how the industry and ourselves work with patient organisations.